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Novel methods for inducing chondrogenesis are critical for cartilage tissue engineering and regeneration.
Here we show that the synthetic oleanane triterpenoids, CDDO-Imidazolide (CDDO-Im) and CDDO-Ethyl
amide (CDDO-EA), at concentrations as low as 200 nM, induce chondrogenesis in organ cultures of
newborn mouse calvaria. The cartilage phenotype was measured histologically with metachromatic
toluidine blue staining for proteoglycans and by immunohistochemical staining for type II collagen.
Furthermore, real-time polymerase chain reaction (PCR) analysis using mRNA from calvaria after 7-day
treatment with CDDO-Im and CDDO-EA showed up-regulation of the chondrocyte markers SOX9 and
type II collagen (alpha1). In addition, TGF-b; BMPs 2 and 4; Smads 3, 4, 6, and 7; and TIMPs-1 and -2 were
increased. In contrast, MMP-9 was strongly down-regulated. Treatment of human bone marrow-derived
mesenchymal stem cells with CDDO-Im and CDDO-EA (100 nM) induced expression of SOX9, collagen
IIa1, and aggrecan, as well as BMP-2 and phospho-Smad5, conﬁrming that the above triterpenoids induce
chondrogenic differentiation. This is the ﬁrst report of the use of these drugs for induction of
chondrogenesis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
It is important to ﬁnd new ways to induce chondrogenesis, for
many practical applications. Here, we have used newborn mouse
calvarial organ cultures and human bone marrow-derived mesen-
chymal stem cell cultures (BMSC) as systems to evaluate the
potential of new drugs, synthetic oleanane triterpenoids (SO), for
chondrogenesis. New SO have been synthesized and developed as
anti-inﬂammatory agents1,2 and one SO, CDDO-Methyl ester (bar-
doxolone methyl), is now in Phase III clinical trial for treatment of
advanced kidney disease3. SO are also known to induce differen-
tiation in many different cell types in monolayer culture4, but they
have not previously been evaluated for chondrogenic activity.
There is a strong rationale for the potential use of SO as chondro-
genic agents, since they are already known to enhance signaling by
bothTGF-b andBMPs5, andbothof these cytokines and their signaling: M.B. Sporn, Department of
r, NH 03755, United States.
.B. Sporn).
s Research Society International. Pproteins (Smads) are known to play important roles in chondro-
genesis6. Here, we report for the ﬁrst time the ability of two new SO,
namely CDDO-Ethyl amide (CDDO-EA) and CDDO-Imidazolide
(CDDO-Im) to induce chondrogenesis, as measured in organ
cultures, both histologically and with classic markers of cartilage.
These SO also successfully differentiate mesenchymal stem cells into
chondrocytes. Thus, the studies reported here have been started with
a long-term goal of developing new triterpenoids that could eventu-
ally be used for various diseases, including osteoarthritis, in which
enhancement of chondrogenesis might be therapeutically useful.
Materials and methods
Reagents
The synthesis of the triterpenoids has been described1,2. All
other chemicals were from SigmaeAldrich.
Calvarial organ cultures
Details have been published previously7,8. Calvaria were
cultured in BGJ medium supplemented with 1 mg/mL of bovineublished by Elsevier Ltd. All rights reserved.
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streptomycin, and 0.292mg/mL of glutamine. On Day 1, the calvaria
were treated with SO. On Day 4, the medium was replaced with
fresh medium, again containing SO. On Day 7, calvaria were
collected, either stored at80C for further RNA analysis or ﬁxed in
10% buffered formalin for 24 h and transferred to 80% ethanol for
histologic analysis.
Histologic analysis of calvaria
After ﬁxation for 24 h, calvaria were decalciﬁed in EDTA,
embedded in parafﬁn and sectioned at 4 mm. Sections were stained
either with modiﬁed hematoxylin and eosin (H&E)8 or with tolui-
dine blue (1% in 70% ethanol for 20 min, followed by destaining in
70%, 90% and 100% ethanol for 15 s), placed in xylene twice, and then
mounted. Procedures for immunoﬂuorescence staining have been
described9. Primary antibodies against collagen type II (AB746P,
Millipore), were used at 1:100 dilution; AlexFluor secondary anti-
bodies (Invitrogen) at 1:200 dilution. For nuclear staining, To-PRO-3
Iodide (T3605, Invitrogen) was used.
Bone marrow-derived stem cell culture and immunoblotting
Human bone marrow-derived stromal cells, which contain
a population of responsive mesenchymal stem cells (ScienCell
Research Laboratories), were grown in mesenchymal stem cell
medium (ScienCell Research Laboratories). Cells were serum-
starved 24 h prior to all experimental conditions. Immunoblotting
was performed using the following antibodies at concentrations
(and using protocols) recommended by the respective manufac-
turers: SOX9 (sc-20095, Santa Cruz Biotechnology), collagen IIa1
(sc-7764 and sc-28887, Santa Cruz), aggrecan (ab3778 and ab36861,
Abcam), BMP-2 (ab14933, Abcam), phospho-Smad5 (9516, Cell
Signaling Technology), Smad5 (9517, Cell Signaling Technology),
b-actin (A1978, SigmaeAldrich). HRP-conjugated IgG TrueBlot
reagents (18-8814, eBioscience) were used at a dilution of 1:1000.
Quantitative RT-PCR
Detailed procedures have been previously published10. In brief,
30 ng of RNA was reverse transcribed to cDNA using the random
primers and Applied Biosystems’ High Capacity cDNA Archive Kit in
a 96-well format Mastercycler Gradient from Eppendorf. Then,
cDNA was ampliﬁed with Assays-on-Demand Products containing
two gene speciﬁc primers and one TaqManMGB probe (6-FAM dye-
labeled) using the TaqMan Universal PCR Master Mix in an ABI
Prism 7000 Sequencing Detector (Applied Biosystems). All labeled
primers were obtained from Applied Biosystems.
Results
For the results described here, we have performed more than
300 individual calvarial organ cultures. Figure 1(A) shows that both
CDDO-Im and CDDO-EA have marked ability to induce chondro-
genesis in newborn mouse calvaria. Because it is membranous
bone, the newborn calvarium does not manifest the chondrogenic
phenotype, except for a very thin margin at suture lines; we have
been careful to avoid using suture areas of calvaria in any of the
analyses described below. Treatment with either triterpenoid
(200 nM) for 7 days clearly has a profound chondrogenic effect on
the calvaria. No new cartilage is seen on control sections stained
with either H&E or toluidine blue. In contrast, the metachromatic
toluidine blue purple staining, seen in Fig. 1(A), is indicative of the
ability of CDDO-Im and CDDO-EA to induce the formation ofproteoglycans, such as aggrecan, which are characteristic of carti-
lage11. With toluidine blue, bone stains orthochromatically (blue).
With respect to dose-response to either SO, 200 nM appears to
be optimal. Treatment with 50 nM triterpenoid yielded only
marginal induction of chondrogenesis, while treatment with
500 nM SO gave somewhat variable results. Treatment with 1 mM
triterpenoid was invariably toxic to the organ cultures. Results
shown in Fig. 1(A) with 200 nM CDDO-Im and CDDO-EA were
obtained in at least three sets of replicate experiments. Figure 1(B)
shows immunohistochemically that CDDO-Im and CDDO-EA
(200 nM) both induce the formation of type II collagen (collagen
IIa1), which is not seen in the control sections.
In addition to the histologic analysis of the calvarial cultures, we
have investigated some mechanistic aspects of the action of both
CDDO-EA and CDDO-Im in the calvaria. After 7 days of culture, RNA
was isolated from the calvaria and quantitative RT-PCR analysis was
performed for more than 15 different markers, including: SOX9,
collagen IIa1, all three isoforms of TGF-b, BMPs 2 and 4, BMP
receptor II, Smads 3, 4, 6, and 7, tissue inhibitors of metal-
loproteinases (TIMP-1 and TIMP-2), and matrix metalloproteinase-
9 (MMP-9). Table I shows that essentially all of these markers
(except MMP-9) are signiﬁcantly up-regulated by both triterpe-
noids, when the calvaria were treated at either the 200 or the
500 nM dose. The 50 nM dose was generally ineffective. In contrast,
both triterpenoids are strong inhibitors of the expression of
MMP-9; CDDO-EA (200 nM) caused almost 80% inhibition of the
expression of this metalloproteinase, which is known to be
involved in the degradation of cartilage12.
Further studies on mechanism were pursued in human BMSC
cultures. Thus, the Western blots in Fig. 1(C) show that CDDO-Im
and CDDO-EA (each 100 nM for 7 days) induce expression of the
chondrocyte markers, SOX9, collagen type 2, and aggrecan, none of
which are detectable in the control cultured stem cells. Further-
more, Fig. 1(D) shows that both triterpenoids (also at 100 nM)
rapidly induce expression of both BMP-2 and its relevant signal
transduction protein, phospho-Smad5 (P-Smad5), in these stem
cells. BMP-2 is known to induce chondrogenic lineage development
of human mesenchymal stem cells in culture13.
Discussion
Our results clearly show that both CDDO-Im and CDDO-EA
induce chondrogenesis in calvarial organ cultures, as evaluated
both morphologically and with biochemical markers of the
expression of the cartilage phenotype. Cultures of mesenchymal
stem cells treated with these drugs also show chondrogenic
differentiation. In the stem cells, concentrations of CDDO-Im and
CDDO-EA as low as 100 nM strongly induce expression of type II
collagen and aggrecan, as well as the transcription factor, SOX9,
which is critical for the cartilage phenotype14,15. None of these
markers are seen in the vehicle-treated (control) stem cells.
In this initial report, we have not extensively addressed the
underlying mechanisms whereby the triterpenoids induce the
chondrogenic phenotype. This will be a complex problem, at both
the molecular and the cellular level. Although it is well known that
SO can induce differentiation (myeloid, adipogenic, and neuronal)
in a variety of cells in culture4, the molecular mechanisms involved
are still obscure. This is undoubtedly a reﬂection of the fact that SO
are multifunctional agents that interact with many molecular
targets in the cell2,16. In almost all cases, it has been shown that the
binding of any SO to its protein target involves an active cysteine
residue in the target1,2. Recent proteomic analysis has identiﬁed
several hundred proteins that bind SO in human embryonic kidney
cells16. Targets of SO that are already known include Keap1/Nrf2,
IkB kinase/NFkB, proteins that are involved with estrogen receptor
Fig. 1. (A) Histology of calvaria after 7 days of culture. CDDO-Im and CDDO-EA, 200 nM. Toluidine blue stains bone orthochromatically (blue staining, noted by black arrowheads);
cartilage is metachromatic (purple staining, noted by open arrowheads). Essentially similar results were found in three separate experiments. (B) Same cultures stained for type II
collagen (COL2A1). Details for ﬂuorescence immunohistochemistry9 are in Materials and methods section. Collagen is stained red. (C) and (D) Immunoblotting of human bone
marrow-derived stem cells after 7 days in culture (C), or after 1 or 12 h (D). CDDO-Im and CDDO-EA, 100 nM. Details of cell culture and immunoblotting9 are in Materials and
methods section. b-actin was used as a loading control. Essentially similar results were found in three separate experiments.
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signaling, JAK/Stat signaling, PTEN signaling, retinoic acid receptor
activation, IGF-1 signaling, and the actions of several interleukins,
as well as proteins associated with the actin-cytoskeleton of the
cell16. The recent identiﬁcation of the mTOR pathway as a func-
tional target of CDDO-Im is particularly noteworthy16.
The present studies again conﬁrm the ability of SO to up-
regulate the activity of TGF-b and BMPs5. The rapid induction of
the expression of BMP-2 and phospho-Smad5 is particularly
germane to mechanisms of chondrogenesis13. Thus, it appears that
therewill be no simple singlemolecular target of the SO that will be
able to explain their induction of the chondrogenic phenotype.The nature of the stem cell that responds to CDDO-Im and CDDO-
EA in the context of the calvarial organ cultures is also unknown
at present. This is clearly an important problem that will need
further investigation. However, our present ﬁnding that bone
marrow-derived stromal cells, a subset of which are stem cells,
respond chondrogenically to SO opens the door to further mecha-
nistic analysis of the effects of SO on stem cells.
The possible application of our present ﬁndings to practical
problems in cartilage pathology is perhaps the biggest challenge at
the present time. Clearly, one could conceive of numerous practical
beneﬁts if the initial ﬁndings that we have described here could be
translated into studies in vivo. This will require extensive
Table I
Quantitative RT-PCR analysis on calvaria
Gene CDDO-Im CDDO-EA
50 nM 200 nM 500 nM 50 nM 200 nM 500 nM
SOX9 1.26  0.08 1.33  0.05 1.83  0.13** 1.64  0.17 2.62  0.33** 3.12  0.38**
COL2A1 1.45  0.09 1.32  0.23 1.72  0.39 4.12  1.78* 5.45  1.13** 3.18  0.71
TGF-b1 0.96  0.07 1.08  0.12 1.46  0.12* 1.17  0.09 1.47  0.24* 1.74  0.17**
TGF-b2 1.17  0.05 1.15  0.09 1.17  0.10 1.36  0.13* 1.61  0.11** 1.88  0.09**
TGF-b3 1.30  0.07 1.52  0.16** 1.66  0.13** 1.39  0.07* 1.56  0.13** 1.44  0.11**
BMP-2 1.17  0.07 1.60  0.19 3.14  0.53** 1.53  0.20 2.52  0.29** 5.66  0.67**
BMP-4 0.97  0.05 0.98  0.06 1.35  0.22 1.28  0.12 1.47  0.13 2.49  0.35**
BMPRII 1.09  0.06 1.22  0.11 1.46  0.14* 1.50  0.14* 1.71  0.19** 2.24  0.22**
Smad3 0.97  0.07 0.90  0.05 1.35  0.19 1.14  0.12 1.35  0.07 1.93  0.16**
Smad4 0.96  0.06 1.03  0.09 1.26  0.09 1.06  0.03 1.37  0.12** 1.89  0.12**
Smad6 0.95  0.05 1.23  0.14 1.77  0.19** 1.09  0.04 1.77  0.24** 2.85  0.31**
Smad7 1.05  0.07 1.32  0.14 1.78  0.18** 1.28  0.10 1.86  0.19** 3.06  0.28**
TIMP-1 1.43  0.19 1.83  0.18 3.00  0.65** 1.88  0.34 2.85  0.38** 4.65  0.38**
TIMP-2 1.24  0.10 1.67  0.19 2.62  0.29** 1.78  0.18* 2.44  0.31** 4.09  0.36**
MMP-9 0.73  0.16 0.44  0.12** 0.26  0.03** 0.49  0.09** 0.22  0.03** 0.19  0.06**
N¼ 20 calvaria for control group and N¼ 12 calvaria per treatment group. Statistical signiﬁcance was performed with ANOVA followed by Dunnett’s multiple comparison test
using GraphPad Prizm 4.0 software. Data are represented as average S.E. (*P < 0.05, **P < 0.01). Methods for isolation of RNA and RT-PCR are described in ref10. All values
have been normalized to the 20 control cultures, assigned a value of 1.00.
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Most notably, the availability of numerous mouse models of oste-
oarthritis in which a defect in cartilage plays a causal role now
offers the opportunity to pursue this line of research. In addition to
the anabolic effects described here, SO are known to be potent anti-
inﬂammatory agents1,2, which should add to their potential
usefulness in prevention or treatment of osteoarthritis. The prom-
ising clinical results that have already been obtained with CDDO-
Methyl ester3, together with extensive beneﬁts of both CDDO-Im
and CDDO-EA in other animal studies, provide optimism for
further studies in the area of osteoarthritis and cartilage.
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